This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
Gill A. Webster, PhD
Advertisement
Gill A. Webster, PhD, is chief scientific officer at Virionyx Corporation Ltd.
Articles by Gill A. Webster, PhD
Advertisement
Latest Updated Articles
The Therapeutic Vaccine Potential of MIS416 AdjuvantPublished: January 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
2
Establishing Risk Assessments for AI in Bio-Manufacturing
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
5
